Literature DB >> 15217542

Neuroimaging of Parkinson's disease and atypical parkinsonism.

Dennis J Zgaljardic1, Andrew Feigin.   

Abstract

The basal ganglia and its associated circuitry can be assessed with a variety of neuroimaging methods that can provide information regarding specific neurotransmitter systems, the functional activity of brain regions, and the structural integrity of these regions. In Parkinson's disease (PD) and related atypical parkinsonian syndromes (APS), these imaging methods may be useful for many reasons, including aiding in differential diagnosis and measuring the efficacy of new therapies. This paper reviews recent developments in the application of neuroimaging to the assessment of PD and related APS.

Entities:  

Mesh：

Year:  2004        PMID： 15217542     DOI： 10.1007/s11910-004-0053-1

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN： 1528-4042            Impact factor:   5.081


  65 in total

Review 1.  Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions.

Authors:  G E Alexander; M D Crutcher; M R DeLong
Journal:  Prog Brain Res       Date:  1990       Impact factor: 2.453

2.  Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease.

Authors:  A Antonini; K L Leenders; P Vontobel; R P Maguire; J Missimer; M Psylla; I Günther
Journal:  Brain       Date:  1997-12       Impact factor: 13.501

3.  Routine MRI for the differential diagnosis of Parkinson's disease, MSA, PSP, and CBD.

Authors:  F Yekhlef; G Ballan; F Macia; O Delmer; C Sourgen; F Tison
Journal:  J Neural Transm (Vienna)       Date:  2003-02       Impact factor: 3.575

4.  Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study.

Authors:  E Nurmi; J Bergman; O Eskola; O Solin; S M Hinkka; P Sonninen; J O Rinne
Journal:  J Cereb Blood Flow Metab       Date:  2000-11       Impact factor: 6.200

Review 5.  Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease.

Authors:  D J Brooks; K A Frey; K L Marek; D Oakes; D Paty; R Prentice; C W Shults; A J Stoessl
Journal:  Exp Neurol       Date:  2003-11       Impact factor: 5.330

6.  123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.

Authors:  A Antonini; R Benti; R De Notaris; S Tesei; A Zecchinelli; G Sacilotto; N Meucci; M Canesi; C Mariani; G Pezzoli; P Gerundini
Journal:  Neurol Sci       Date:  2003-10       Impact factor: 3.307

7.  Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.

Authors:  Alan L Whone; Ray L Watts; A Jon Stoessl; Margaret Davis; Sven Reske; Claude Nahmias; Anthony E Lang; Olivier Rascol; Maria J Ribeiro; Philippe Remy; Werner H Poewe; Robert A Hauser; David J Brooks
Journal:  Ann Neurol       Date:  2003-07       Impact factor: 10.422

8.  Brain perfusion SPECT in patients with corticobasal degeneration: analysis using statistical parametric mapping.

Authors:  A K M Moinul Hossain; Yuji Murata; Lin Zhang; Shin-ichi Taura; Yukinobu Saitoh; Hidehiro Mizusawa; Kenji Oda; Eisuke Matsushima; Yoshiro Okubo; Hitoshi Shibuya
Journal:  Mov Disord       Date:  2003-06       Impact factor: 10.338

9.  The metabolic topography of parkinsonism.

Authors:  D Eidelberg; J R Moeller; V Dhawan; P Spetsieris; S Takikawa; T Ishikawa; T Chaly; W Robeson; D Margouleff; S Przedborski
Journal:  J Cereb Blood Flow Metab       Date:  1994-09       Impact factor: 6.200

10.  [A follow-up study on brainstem atrophy in progressive supranuclear palsy--when does brain MRI contribute to the differential diagnosis between progressive supranuclear palsy and Parkinson disease?].

Authors:  Toshiyuki Yamamoto; Yasushi Oya; Masafumi Ogawa; Katsuhisa Ogata; Mitsuru Kawai
Journal:  Rinsho Shinkeigaku       Date:  2003-07
View more
  4 in total

1.  An examination of executive dysfunction associated with frontostriatal circuitry in Parkinson's disease.

Authors:  Dennis J Zgaljardic; Joan C Borod; Nancy S Foldi; Paul J Mattis; Mark F Gordon; Andrew Feigin; David Eidelberg
Journal:  J Clin Exp Neuropsychol       Date:  2006-10       Impact factor: 2.475

2.  Frontotemporal Lobe Degeneration as Origin of Scans Without Evidence of Dopaminergic Deficit.

Authors:  Manuel Menéndez-González; Tania Álvarez-Avellón; José M Salas-Pacheco; Benito de Celis-Alonso; Kathryn A Wyman-Chick; Oscar Arias-Carrión
Journal:  Front Neurol       Date:  2018-05-24       Impact factor: 4.003

3.  Diagnoses behind patients with hard-to-classify tremor and normal DaT-SPECT: a clinical follow up study.

Authors:  Manuel Menéndez-González; Francisco Tavares; Nahla Zeidan; José M Salas-Pacheco; Oscar Arias-Carrión
Journal:  Front Aging Neurosci       Date:  2014-04-01       Impact factor: 5.750

4.  Distinguishing Parkinson's disease from atypical parkinsonian syndromes using PET data and a computer system based on support vector machines and Bayesian networks.

Authors:  Fermín Segovia; Ignacio A Illán; Juan M Górriz; Javier Ramírez; Axel Rominger; Johannes Levin
Journal:  Front Comput Neurosci       Date:  2015-11-05       Impact factor: 2.380
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.